When median doesn’t mean what it seems
When interpreting brain scans, the eyes can deceive. A numbers dispute over a potential Alzheimer's disease test in Eli Lilly & Co.'s pharmaceutical pipeline broke out in the pages of a prestigious medical journal last week. The test, which holds the potential to diagnose the presence of Alzheimer's-linked protein accumulation in the brain in living patients, has to be interpreted by doctors. Three physicians were enlisted by researchers conducting a Lilly-funded study to put a number on what they saw in scans, and they didn't always see eye to eye. The debate, and the fate of this test, matters greatly to people with dementia and their loved ones. It also sheds light on the use and potential abuse of median, a common statistical concept. While median can be very useful in analyzing and summarizing a large data set, it might obscure the results for individual cases.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- WellPoint Dominates Nearly Half of Markets, AMA Says
- Defensive Medicine Still Prevalent Despite Tort Reform
- CMS Offers Some ACOs $114M for 'Upfront' Costs